



**Lexaria Bioscience Corp.    LXX:CSE | LXR:US**  

---

**Drug Delivery Platform Innovator**

Investor Presentation  
December 2018  
[LexariaBioscience.com](http://LexariaBioscience.com)


# Disclaimer

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, evaluation of medical marijuana projects, alternative health projects or products, and cannabidiol-fortified products or services for participation and/or financing, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements including, without limitation, foreign exchange and other financial markets; changes of the interest rates on borrowings; whether or not the Company will be successful in executing its business plan in whole or in part; hedging activities; changes in commodity prices; changes in the marketing or capital project expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Lexaria Corp. operates. These and other risks and uncertainties are more fully described in our periodic reports and other disclosure documents filed by Lexaria Corp. from time to time with regulatory authorities available on SEDAR at [www.sedar.com](http://www.sedar.com) and on EDGAR at [www.sec.gov](http://www.sec.gov), and the reader is encouraged to review these documents. Planned dates stated herein are estimates only, based on best information available. Dates are not assured and are subject to revision without notice. The Company assumes no obligation, except as required by law, to update any forward-looking statement, whether as a result of new information, future events or otherwise. This presentation is not an offer to sell or a solicitation of an offer to buy securities of Lexaria Bioscience Corp. It is a short summary of certain information for introductory purposes only and is not to be relied upon for investment purposes.

No statement within has been evaluated by the Food and Drug Administration, and no product or service is intended to diagnose, treat, cure or prevent any disease.

# Drug Delivery Platform Innovator


**DehydraTECH™ - Patented technology,  
Changing the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally**



Eliminates the need for sugar-filled edibles.



Effects are felt within 10-20 min (vs. 60-120 min).



Equates that of less healthy administration methods like inhalation



Easy to implement

# DehydraTECH™ Patent Portfolio

50+  
Patent Applications  
10  
Patent Families

10  
Patents Granted  
6 USA  
4 Australia

Method of use &  
Composition of matter claims

- Cannabinoids (CBD, THC)
- Nicotine (and its analogs)
- NSAIDs
- Fat soluble vitamins

Multiple dosage forms - foods, liquid emulsions, tablets, capsules



# Commercial Applications

## Cannabis



- Ingestible product formats of all types,
- Enhanced palatability, speed of effectiveness and potency,
- Viable and healthier alternative to smoking/vaping.

## Vitamins




- Existing and new ingestible product formats,
- Enhanced absorption performance for synthetics as well as natural fat soluble vitamins (A, D, K & E).

## NSAIDs



- Alternate means to formulate NSAIDs,
- Higher bioavailability,
- Lower input requirements,
- Less burden on liver and kidneys (lower toxicity).

## Nicotine



- World's first ingestible nicotine products,
- Alternative to smoking/vaping, gums and patches,
- High bioavailability without first pass liver metabolism.

### Estimated Global Market Sizes

\$13B

\$31B

\$60B

\$990B

Sources: ArcView Research & EuroMonitor

# Cannabinoids: Entering the Blood Stream

3 prominent ways cannabinoids enter the blood stream:




**Inhalation**  
High bioavailability (est. 30%)  
Harmful to Lungs



**Sub-lingual (under tongue)**  
Medium bioavailability (est. 16%)  
Foul taste



**Oral – Gastrointestinal Tract**  
Low bioavailability (est. 3-5%)  
Sugar filled, to mask taste



**DehydraTECH™**  
transforms the way  
cannabinoids enter the  
bloodstream through the  
Gastrointestinal Tract  
Fast Acting  
Improved Taste  
Increased Bioavailability



# Cannabinoid Absorption - Clinically Proven



European human clinical study



Double-blind  
90 mg dose




317% more CBD  
delivered  $\leq 30$  min.




Higher CBD delivery  
throughout entire study



### Plasma Concentration Comparison



# Cannabis Consumption Trends







# Business Model: Royalties & Sales

## Demonstration products

TurboCBD™ capsules

ViPova™ teas

Distribution partnerships





## Innovation & Research

New product development

Patent applications

Clinical trials



## Out-license to third-party partners

High margin royalty model

Sample licensees:

[www.1906newhigh.com](http://www.1906newhigh.com)

[www.hillstreetbeverages.com](http://www.hillstreetbeverages.com)



# Nicotine: a smoke-free future?

1.1 billion  
smokers globally  
7 million  
deaths/year globally  
1 billion  
deaths expected this century

Smoking is the  
world's leading  
cause of  
preventable  
death

## FDA

Comprehensive regulatory  
plan to shift trajectory of  
tobacco-related disease,  
death

lowering  
nicotine in  
cigarettes to  
non-  
addictive  
levels

British  
American  
Tobacco  
to rapidly expand  
"next-gen products"

Phillip  
Morris  
pledges \$1B to  
anti-smoking


"Ultimately, we want  
to be in a position to **stop  
selling cigarettes  
entirely.**"  
-- André Calantzopoulos,  
Phillip Morris CEO,  
May 30, 2018.

## No Nicotine edibles


due to nicotine's  
inability to securely  
pass through the GI  
tract without irritation.

# Nicotine: *In vivo* research


**Speed of onset** is of particular importance when considering non-inhalation nicotine delivery formats  
**DehydraTECH™** delivered:



Study of 40 lab rats, with  
focus on initial 15 minute  
period after dosing.  
August 7, 2018




Study of 12 lab rats over 6  
hour period showed  
560% more nicotine  
delivered into brain tissue  
April 17, 2018



179% gain in the quantity  
of peak nicotine delivery  
to the bloodstream  
relative to controls

# Nicotine: Blood-Brain-Barrier Results

Significant nicotine absorption increase across the Blood-Brain Barrier into brain tissue:



# Key Executives



**Chris Bunka**  
Chairman & CEO

Serial entrepreneur involved in several private and public companies since the late 1980's,  
Extensive experience in the capital markets, corporate governance, M&A and finance.



**John Docherty, M.Sc.**  
Director & President

Experienced executive in the pharmaceutical and bioscience sectors, Specialist in development of drug delivery technologies,  
Former President and COO of Helix BioPharma Corp. (TSX: HBP).  
Named inventor on multiple issued and pending patents.  
M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto.



**Dr. Edward Ergenzinger**  
Chief Legal, SVP Innovation

U.S. licensed patent attorney, Doctorate in Neuroscience (with concentrations in Pharmacology and Physiology),  
Over 15 years of experience providing patent services to clients that have ranged from small start-ups to some of the world's largest pharmaceutical and biotechnology companies.




**Dr. Philip Ainslie**  
Advisor

Co-Director for the Centre for Heart, Lung and Vascular Health, Canada, Research Chair in Cerebrovascular Physiology and Professor, School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

# Corporate Information

<b>Trading symbol:</b>	<b>LXX:CSE, LXP:OTCQX</b>
Shares o/s:	77 m
Fully diluted:	85 m
Recent price:	C\$1.70 / US\$1.30
Insider ownership:	15m (20%)
Fiscal year-end:	August 31
Cash on hand (May '18)	US\$ 2M
Recent financing (Oct '18)	US\$1.5M (US\$1.60/unit)

One year stock chart – OTCQX:LXP



<b>Chris Bunka</b>	<b>John Docherty</b>	<b>Alex Blanchard</b>
CEO	President	Manager Corp. Comm & IR
250 765 6424	905 439 5423	778 796-1897
<a href="mailto:Cbunka@lexariabioscience.com">Cbunka@lexariabioscience.com</a>	<a href="mailto:Jdocherty@lexariabioscience.com">Jdocherty@lexariabioscience.com</a>	<a href="mailto:Ablanchard@lexariabioscience.com">Ablanchard@lexariabioscience.com</a>